AI for Pharma & Life Sciences
Converteo Launches Specialized AI Offering Internationally for Pharma & Life Sciences Industry
Converteo, a data and AI consulting firm with over 450 experts, has launched a dedicated AI and Agentic Systems Offering for the Pharma & Life Sciences industry, available across France, Italy, Spain, the United States, and Canada Financial Post. The initiative is led by new Partner Vanessa de Langsdorff, a 15-year veteran of regulated industry consulting who previously served as VP of Customer Success at Yseop, a generative AI firm specializing in automated regulatory documents National Post.
The launch targets one of AI's fastest-growing investment sectors. According to Ottawa Sun, the pharmaceutical industry has become one of the world's largest investors in AI, with 73% of global pharma organizations already planning or piloting so-called "agentic" AI initiatives — systems that act autonomously rather than simply respond to prompts.
What "Agentic AI" Means for Drug Development
Traditional AI tools in pharma help researchers search data or draft text. Agentic AI goes further — it plans and executes multi-step tasks on its own, without constant human input. Think of it as moving from a smart assistant to an autonomous worker. Calgary Sun reports that Converteo's offering is designed to help healthcare companies "automate complex workflows" and bring therapies to patients faster while meeting strict regulatory rules.
The offering targets three major bottlenecks in pharma: drug discovery, clinical trial recruitment, and regulatory documentation. Regulatory filings — the paperwork required before a drug can reach patients — can take months of expert labor. By automating that process, Converteo says companies can get to market weeks earlier and cut significant costs Brantford Expositor.
Vanessa de Langsdorff Brings a Rare Regulatory AI Pedigree
De Langsdorff's background makes her an unusual hire for a consulting firm. Her time at Yseop — a company that specializes in automating the exact type of regulated medical writing pharma requires — gives Converteo a specific edge, according to Mitchell Advocate. Her role was not just advisory. She led large-scale AI implementation programs for enterprise clients in heavily regulated industries.
Converteo CEO Jérémie Lévy has said the firm has needs "at all experience levels to design and deploy autonomous agents at scale." De Langsdorff's appointment signals the offering is built for the most complex, high-stakes part of pharma AI — regulatory approval — rather than general-purpose automation Ottawa Sun.
Google Cloud Partnership Powers the Five-Market Rollout
Converteo built the offering on top of a decade-long alliance with Google Cloud. The partnership is meant to ensure what the firm calls "production-grade" security and performance — a critical bar in an industry where data errors can delay drug approvals or harm patients Fairview Post. The five target markets — France, Italy, Spain, the US, and Canada — cover both the FDA and EMA regulatory environments.
Prince George Post notes that Converteo has already proven agentic AI works at scale outside pharma. In late 2025, the firm built an autonomous system for L'Oréal that analyzed millions of creative assets. That track record is key to winning over pharma clients who are skeptical of vendors promising AI results they cannot yet deliver.
A Crowded Market With Real Cost Stakes
Converteo is entering a competitive but hungry market. PwC analysts estimate that agentic AI in pharma front offices could cut operational costs by up to 40%. That number explains why 73% of pharma companies are already moving in this direction, according to a 2025 Medable report cited by Northern News.
Not everyone is a believer yet. Gartner researchers warn that true autonomous AI workforces are still in early stages, and some current products are little more than basic wrappers around large language models. The real test for Converteo will be whether its offering delivers the "measurable operational impact within weeks" it is promising to pharma clients The Observer.
Sentiment
NeutralPublishers
12
Articles
12
Reach
12
